| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
JBC, Vol. 250, Issue 2, 388-395, Jan, 1975
R. Radcliffe and Y. Nemerson
Factor VII purified as previously described, was found to consist of two polypeptide chains joined by disulfide bridges. We now report the isolation and 200,000-fold purification of a single chain form of Factor VII. This was accomplished by protecting the molecule against proteolysis by including benzamidine during the entire purification. The purification was essentially as previously reported except that barium cirtate was substituted for barium sulfate as an absorbant for Factor VII as it resulted in a 4-fold increase in yield. Single chain Factor VII is rapidly hydrolyzed by Factor Xa in the presence of calcium ions and phospholipids, and by thrombin, to a two-chain form which possesses at least 85 times the Factor VII clotting activity of the single chain species. The two-chain form of the enzyme requires tissue factor in order to activate Factor X. From the observed rates of activation of Factor VII by Xa in the presence of clacium ions and phospholipids, it was claculated that at approximately physiological concentration, Factor VII activity would increase at an initial rate of 20-fold per min; this reaction is sufficiently rapid to constitute a feedback control mechanism. The action of thrombin is approximately 40-fold slower under these conditions. Diisopropylphosphorofluoridate inactivates the single chain and two-chain forms of Factor VII at approximately equal rates. After inhibition, the single chain species could be cleaved but not activated by proteolysis.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kjalke, A. Silveira, A. Hamsten, U. Hedner, and M. Ezban Plasma Lipoproteins Enhance Tissue Factor-Independent Factor VII Activation Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1835 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. van 't Veer, N. J. Golden, and K. G. Mann Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa Blood, February 15, 2000; 95(4): 1330 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Stauffer, B. N. Chukwumezie, J. A. Wilberding, E. D. Rosen, and F. J. Castellino Characterization of Transcriptional Regulatory Elements in the Promoter Region of the Murine Blood Coagulation Factor VII Gene J. Biol. Chem., January 23, 1998; 273(4): 2277 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Butenas, C. van `t Veer, and K. G. Mann Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases J. Biol. Chem., August 22, 1997; 272(34): 21527 - 21533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Silveira, F. Karpe, H. Johnsson, K. A. Bauer, and A. Hamsten In Vivo Demonstration in Humans That Large Postprandial Triglyceride-Rich Lipoproteins Activate Coagulation Factor VII Through the Intrinsic Coagulation Pathway Arterioscler. Thromb. Vasc. Biol., November 1, 1996; 16(11): 1333 - 1339. [Abstract] [Full Text]
|
|
|
|
|
|
S. Eichinger, M. Wolzt, B. Schneider, M. Nieszpaur-Los, H. Heinrichs, K. Lechner, H.-G. Eichler, and P. A. Kyrle Effects of Recombinant Hirudin (r-Hirudin, HBW 023) on Coagulation and Platelet Activation In Vivo : Comparison With Unfractionated Heparin and a Low-Molecular-Weight Heparin Preparation (Fragmin) Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 886 - 892. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
